A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)

Trial Profile

A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs 18F DCFPyL (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Acronyms OSPREY
  • Sponsors Progenics Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2016 According to Progenics Pharmaceuticals media release, first patient has been dosed in this study.
    • 07 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top